Meet Leslie, a 42-year-old mother of three children aged 2, 5, and 7. Leslie's oncologist has just informed her that she has Stage III Ovarian Cancer.
Leslie has a 25% chance of living to see her youngest's 7th birthday. Women like Leslie represent the challenge and opportunity for the transformation of ovarian cancer therapies. Many of these women develop multi-drug resistant tumors. This is when cancer cells develop characteristics that resist multiple drugs due to a number of mutations in the cell that limit the effectiveness of current treatment regimens. Finding solutions to this challenge represents a chance to extend the life of women like Leslie.
Nemucore Medical Innovations Inc is a clinical development company dedicated to the development and commercialization of life-saving personalized molecularly-targeted therapeutic focused on Women’s oncology. Nemucore’s molecularly targeted therapeutics have unique design attributes to address multi-drug resistant and recurrent cancer.
Nemucore is actively developing our portfolio of therapies to bring innovative oncology products to market and provide patients like Leslie with life-threatening cancers, a new hope.